[go: up one dir, main page]

MXPA02011410A - Uso de compuestos 1-amino-5-fenilpentan-3-ol y/o 1-amino-6-fenilhexan-3-ol substituidos como medicamentos. - Google Patents

Uso de compuestos 1-amino-5-fenilpentan-3-ol y/o 1-amino-6-fenilhexan-3-ol substituidos como medicamentos.

Info

Publication number
MXPA02011410A
MXPA02011410A MXPA02011410A MXPA02011410A MXPA02011410A MX PA02011410 A MXPA02011410 A MX PA02011410A MX PA02011410 A MXPA02011410 A MX PA02011410A MX PA02011410 A MXPA02011410 A MX PA02011410A MX PA02011410 A MXPA02011410 A MX PA02011410A
Authority
MX
Mexico
Prior art keywords
amino
phenylhexane
phenylpentane
substituted
medicaments
Prior art date
Application number
MXPA02011410A
Other languages
English (en)
Inventor
Bernd Sundermann
Original Assignee
Gr Nenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gr Nenthal Gmbh filed Critical Gr Nenthal Gmbh
Publication of MXPA02011410A publication Critical patent/MXPA02011410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere al uso de al menos un compuesto 1-amino-5-fenilpentan-3-o1 y/o 1-amino-6- fenilhexan-3-o1 substituido y/o uno de los enantiomeros de los mismos y/o uno de los diastereomeros de los mismos y/o una de las sales fisiologicamente tolerables de los mismos para producir un medicamento que tiene un efecto antagonístico de N-metil-D-aspartato (NMDA).
MXPA02011410A 2000-05-22 2001-05-10 Uso de compuestos 1-amino-5-fenilpentan-3-ol y/o 1-amino-6-fenilhexan-3-ol substituidos como medicamentos. MXPA02011410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10025238A DE10025238A1 (de) 2000-05-22 2000-05-22 Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel
PCT/EP2001/005349 WO2001089505A1 (de) 2000-05-22 2001-05-10 Verwendung substituierter 1-amino-5-phenylpentan-3-ol- und/oder 1-amino-6-phenylheyan-3-ol-verbindungen als arzneimittel

Publications (1)

Publication Number Publication Date
MXPA02011410A true MXPA02011410A (es) 2003-06-06

Family

ID=7643080

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011410A MXPA02011410A (es) 2000-05-22 2001-05-10 Uso de compuestos 1-amino-5-fenilpentan-3-ol y/o 1-amino-6-fenilhexan-3-ol substituidos como medicamentos.

Country Status (16)

Country Link
US (1) US6784175B2 (es)
EP (1) EP1289514B1 (es)
JP (1) JP2004509842A (es)
AR (1) AR029091A1 (es)
AT (1) ATE281158T1 (es)
AU (2) AU7402201A (es)
CA (1) CA2406198A1 (es)
DE (2) DE10025238A1 (es)
ES (1) ES2231502T3 (es)
HU (1) HUP0301884A2 (es)
MX (1) MXPA02011410A (es)
NZ (1) NZ521439A (es)
PE (1) PE20011261A1 (es)
PT (1) PT1289514E (es)
UY (1) UY26718A1 (es)
WO (1) WO2001089505A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6856700B1 (en) * 2000-05-24 2005-02-15 Microsoft Corporation Palettized image compression
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
EP2792347A1 (en) * 2005-09-28 2014-10-22 Auris Medical AG Pharmaceutical compositions for the treatment of inner ear disorders
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
US20150044200A1 (en) 2011-12-12 2015-02-12 Otolanum Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US4155935A (en) * 1973-03-26 1979-05-22 American Home Products Corporation Benzylamine analgesics
US4366172A (en) * 1977-09-29 1982-12-28 The Upjohn Company 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
IE913279A1 (en) * 1990-09-26 1992-04-08 Astra Ab (2-Thienyl)alkylamine Derivatives Having Neuroprotective¹Properties
DE19915601A1 (de) * 1999-04-07 2000-10-19 Gruenenthal Gmbh 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
AU7402201A (en) 2001-12-03
JP2004509842A (ja) 2004-04-02
US6784175B2 (en) 2004-08-31
NZ521439A (en) 2005-06-24
EP1289514A1 (de) 2003-03-12
AU2001274022B2 (en) 2004-10-14
ATE281158T1 (de) 2004-11-15
HUP0301884A2 (hu) 2003-09-29
EP1289514B1 (de) 2004-11-03
CA2406198A1 (en) 2002-10-16
WO2001089505A1 (de) 2001-11-29
DE10025238A1 (de) 2001-11-29
PE20011261A1 (es) 2002-01-26
DE50104405D1 (de) 2004-12-09
UY26718A1 (es) 2001-06-29
ES2231502T3 (es) 2005-05-16
AR029091A1 (es) 2003-06-04
PT1289514E (pt) 2005-02-28
US20030181450A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
DZ3312A1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
MXPA04000577A (es) Derivados de dolastatina 10.
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
BG106586A (en) Pyrazolopyramidines as therapeutic agents
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
CA2129288A1 (en) Phosphonooxymethyl Esters of Taxane Derivatives
BR0211972A (pt) Composição oftálmica
EP1274443A4 (en) MICELLES
EP1222922A4 (en) METHOD FOR STABILIZING BENZIMIDAZOLE COMPOUNDS
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
SI1105105T1 (sl) Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole
GB9424766D0 (en) Pharmaceutical composition
MXPA02011410A (es) Uso de compuestos 1-amino-5-fenilpentan-3-ol y/o 1-amino-6-fenilhexan-3-ol substituidos como medicamentos.
GEP20074127B (en) Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
MXPA05010783A (es) Derivados antimicrobianos de [3.1.0] biciclohexilfenil-oxazolidinona y analogos.
BRPI0412239A (pt) sistemas emulsificantes contendo derivados de azetidina
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
ATE241968T1 (de) Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren

Legal Events

Date Code Title Description
FG Grant or registration